American College of Rheumatology, American Academy of Dermatology, Rheumatologic Dermatology Society, and American Academy of Ophthalmology 2020 Joint Statement on Hydroxychloroquine Use With Respect to Retinal Toxicity-Reference-Cited by-同舟云学术

American College of Rheumatology, American Academy of Dermatology, Rheumatologic Dermatology Society, and American Academy of Ophthalmology 2020 Joint Statement on Hydroxychloroquine Use With Respect to Retinal Toxicity

Published:2021-04-26 Issue:6 Volume:73 Page:908-911
ISSN:2326-5191
Container-title:Arthritis & Rheumatology
language:en
Short-container-title:Arthritis Rheumatol

Author:

Rosenbaum James T.¹^ORCID,Costenbader Karen H.²,Desmarais Julianna³,Ginzler Ellen M.⁴,Fett Nicole³,Goodman Susan M.⁵^ORCID,O’Dell James R.⁶,Schmajuk Gabriela⁷^ORCID,Werth Victoria P.⁸^ORCID,Melles Ronald B.⁹,Marmor Michael F.¹⁰

Affiliation:

1. Oregon Health & Science University and Legacy Devers Eye Institute Portland

2. Brigham and Women’s Hospital Boston Massachusetts

3. Oregon Health & Science University Portland

4. SUNY Downstate Health Sciences University Brooklyn New York

5. Hospital for Special Surgery and Weill Cornell Medicine New York New York

6. University of Nebraska Medical Center and VA Nebraska–Western Iowa Health Care System Omaha

7. University of California and VA Medical Center San Francisco

8. University of Pennsylvania and Corporal Michael J. Crescenz VAMC Philadelphia

9. Kaiser Permanente Redwood City California

10. Stanford University Medical Center Stanford California

Publisher

Wiley

Subject

Immunology,Rheumatology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/art.41683

Reference12 articles.

1. American College of Rheumatology.Position statement: screening for hydroxychloroquine retinopathy.2016. URL:https://www.rheumatology.org/Portals/0/Files/Screening-for-Hydroxychloroquine-Retinopathy-Position-Statement.pdf?ver=2016-10-04-170000-000.

2. Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision)

3. Antimalarial drug toxicities in patients with cutaneous lupus and dermatomyositis: A retrospective cohort study

4. Prevalence of hydroxychloroquine retinopathy using 2018 Royal College of Ophthalmologists diagnostic criteria

5. Somatotype, the risk of hydroxychloroquine retinopathy, and safe daily dosing guidelines

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Non‐biologic immunosuppressive drugs for inflammatory and autoimmune skin diseases;JDDG: Journal der Deutschen Dermatologischen Gesellschaft;2024-01-23

2. Demographic and clinical characteristics associated with screening practices for hydroxychloroquine retinopathy;Scientific Reports;2024-01-10

3. Application of SS- OCTA to evaluate the effects of long- term hydroxychloroquine treatment on retinal structure and microcirculation in patients with systemic lupus erythematosus;2023-12-23

4. Balancing risks and benefits in the use of hydroxychloroquine and glucocorticoids in systemic lupus erythematosus;Expert Review of Clinical Immunology;2023-12-19

5. Advances in the management of systemic lupus erythematosus;BMJ;2023-10-26